# Biological Therapy in Treating Patients With Myelodysplastic Syndrome

> **NCT00005853** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center**

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **BIOLOGICAL:** etanercept

## Key facts

- **NCT ID:** NCT00005853
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** — (—)
- **Last updated:** 2010-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005853, "Biological Therapy in Treating Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00005853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*